G. Richmond

发表

Once-Daily Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir for the Treatment of HIV-1 Infection in Antiretroviral-Naïve Patients: A 48-Week Pilot Study

B. Ha, D. Berger, W. Towner, 2008, HIV clinical trials.

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

W. K. Henry, D. Podzamczer, H. Stellbrink, 2021, Open forum infectious diseases.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

S. Swindells, C. Orrell, Kimberly Smith, 2020, The Lancet.

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

S. Swindells, S. Oka, C. Orkin, 2020, Journal of acquired immune deficiency syndromes.

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

W. Spreen, D. Margolis, A. Mills, 2021, AIDS (London, England).

Recombinant Human Growth Hormone to Treat HIV-Associated Adipose Redistribution Syndrome: 12-Week Induction and 24-Week Maintenance Therapy

C. Grunfeld, D. Kotler, Stephen J Brown, 2007, Journal of acquired immune deficiency syndromes.

Safety/Tolerability and Efficacy of Abacavir-Containing Combination Therapy in HIV-1-Infected Adults in a Clinical Practice Setting: Results of ZORRO

P. Ruane, Arthur L. Williams, Cathy Alsop, 2004 .

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

D. Potvin, S. Grinspoon, D. Kotler, 2007, The New England journal of medicine.

Simplified Maintenance Therapy With Abacavir/Lamivudine and Atazanavir After Discontinuation of Ritonavir

B. Ha, D. Berger, E. Dejesus, 2010, HIV clinical trials.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

R. Haubrich, M. Kozal, K. Tashima, 2014, The Journal of infectious diseases.

Enfuvirtide Does Not Require Dose Adjustment in Patients With Chronic Kidney Failure: Results of a Pharmacokinetic Study of Enfuvirtide in HIV-1-Infected Patients With Impaired Kidney Function

P. Tebas, I. Patel, L. Rowell, 2008, Journal of acquired immune deficiency syndromes.

Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.

M. Lederman, L. Novello, M. Para, 2008, The Journal of infectious diseases.

Pharmacodynamic Effects of Zidovudine 600 mg Once/Day versus 300 mg Twice/Day in Therapy‐Naïve Patients Infected with Human Immunodeficiency Virus

Edwin DeJesus, Qiming Liao, P. Ruane, 2004, Pharmacotherapy.

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression: pOLAR month 12 results.

W. Spreen, D. Margolis, A. Mills, 2021, AIDS (London).

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

D. Podzamczer, B. Clotet, H. Stellbrink, 2017, The Lancet.

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.

P. Cahn, S. Swindells, J. Mrus, 2020, The New England journal of medicine.

Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain

M. Murray, D. Kerrigan, D. Margolis, 2018, PloS one.

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.

J. Baeten, H. Stellbrink, H. Dvory‐Sobol, 2022, The New England journal of medicine.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.

Kimberly Smith, H. Crauwels, E. Overton, 2021, The lancet. HIV.

116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study

W. Spreen, D. Margolis, A. Mills, 2020 .

Phase 3 Study of Ibalizumab for Multidrug‐Resistant HIV‐1

Gary Richmond, S. Weinheimer, Princy Kumar, 2018, The New England journal of medicine.

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

A. LaMarca, B. Clotet, C. Katlama, 2012, The Journal of infectious diseases.

Dolutegravir versus Placebo in Subjects Harbouring HIV-1 with Integrase Inhibitor Resistance Associated Substitutions: 48-Week Results from VIKING-4, a Randomized Study

M. Ramgopal, B. Wynne, B. Akil, 2015, Antiviral therapy.

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

P. Cahn, M. Ramgopal, A. Pozniak, 2013, The Lancet.

Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1

S. Weinheimer, W. Fessel, C. Marsolais, 2017, Open Forum Infectious Diseases.

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients

R. Pollard, J. Gathe, J. Nadler, 2003, BMC infectious diseases.

T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.

G. D. Miralles, C. Cohen, M. Greenberg, 2005, The Journal of infectious diseases.

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation

D. Potvin, S. Grinspoon, D. Kotler, 2008, AIDS.

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

S. Swindells, Kimberly Smith, H. Crauwels, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects

G. D. Miralles, I. Patel, E. Dejesus, 2006, AIDS.

A Controlled Phase Ii Trial Assessing Three Doses of Enfuvirtide (T-20) in Combination with Abacavir, Amprenavir, Ritonavir and Efavirenz in Non-Nucleoside Reverse Transcriptase Inhibitor-Naive HIV-Infected Adults

Gary Richmond, Edwin DeJesus, Richard Haubrich, 2002, Antiviral therapy.